[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@BJLinvestment Compass capital
Compass capital posts on X about $nbis, $hrow, $49m, $200m the most. They currently have XXX followers and XX posts still getting attention that total XXX engagements in the last XX hours.
Engagements: XXX #
- X Week XXXXX +297%
- X Month XXXXX -XX%
Mentions: X #
- X Week X +100%
- X Month XX +57%
Followers: XXX #
- X Week XXX +4.20%
- X Month XXX +9.30%
CreatorRank: XXXXXXXXX #
Social Influence #
Social category influence finance XXXXX% stocks XXXXX% technology brands XXXX% automotive brands XXXX%
Social topic influence $nbis 11.76%, $hrow #9, $49m #4, $200m #97, $280m #5, debt #1661, 200m #107, goldman sachs 5.88%, $dlo 5.88%, stocks XXXX%
Top accounts mentioned or mentioned by @mvcinvesting @grindeoptions @tacticzh @synspective @mastonk123 @daniel_koss
Top assets mentioned Nebius Group N.V. Class A Ordinary Shares (NBIS) Goldman Sachs (GS) DLocal Limited Class A Common Shares (DLO) Tesla, Inc. (TSLA) Morgan Stanley (MS) Rocket Lab USA, Inc. Common Stock (RKLB)
Top Social Posts #
Top posts by engagements in the last XX hours
"Goldman Sachs raised $DLO price target to 19$. We have been accumulating as its one of the cheapest stocks in the market"
X Link @BJLinvestment 2025-10-14T12:57Z XXX followers, XXX engagements
"Bullish for the subsidiary of $NBIS AVRIDE"
X Link @BJLinvestment 2025-10-13T11:18Z XXX followers, XXX engagements
"Breaking 🚨: ClickHouse just extended its Series C 4x ARR growth 2000+ customers and massive AI adoption (Anthropic Meta LangChain Tesla) Guess who benefits 👇 Every surge in real-time analytics & AI workloads = more demand for $NBIS"
X Link @BJLinvestment 2025-10-07T19:51Z XXX followers, XXX engagements
"Breaking🚨: Morgan Stanley has just revised its price target for $RKLB to 68$. It is a good sign but they are late tbh. The investment thesis will materialise likely in the next two years"
X Link @BJLinvestment 2025-10-13T11:57Z XXX followers, XXX engagements
"✅Increasing $HROW: from compounding pharmacy to eye-care leader. VEVYE outpacing CEQUA aiming to dethrone Restasis. Revenue $49M$200M$280M gross margin 6874%. 2025: entering retina debt refinance acquisitions. Niche + unique products + growth = compelling risk/reward"
X Link @BJLinvestment 2025-10-10T10:19Z XXX followers, 2624 engagements
"If $HROW can achieve 250M per quarter in 2027/28 weeks can see it trading at 100$+. Probably the most easy buys in the market right now. ❤"
X Link @BJLinvestment 2025-10-12T21:11Z XXX followers, 1555 engagements